AVELUMAB was accepted for Priority Review by FDA. The drug is sponsored by Merck KGaA, Darmstadt, Germany, which in the US and Canada operates as EMD Serono. The drug is being developed through an alliance between Merck KGaA and and Pfizer Inc. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1...
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
